Federation Des Caisses Desjardins Du Quebec Viking Therapeutics, Inc. Transaction History
Federation Des Caisses Desjardins Du Quebec
- $21.3 Billion
- Q2 2025
A detailed history of Federation Des Caisses Desjardins Du Quebec transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Federation Des Caisses Desjardins Du Quebec holds 13,912 shares of VKTX stock, worth $486,780. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13,912
Previous 13,418
3.68%
Holding current value
$486,780
Previous $324,000
13.58%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding VKTX
# of Institutions
455Shares Held
68.3MCall Options Held
7.72MPut Options Held
3.31M-
Vanguard Group Inc Valley Forge, PA10.2MShares$356 Million0.0% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$211 Million0.01% of portfolio
-
State Street Corp Boston, MA3.78MShares$132 Million0.0% of portfolio
-
Morgan Stanley New York, NY3.25MShares$114 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY3.13MShares$109 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $2.68B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...